We fit the capital raising instrument to our client's needs
Research
In-depth knowledge of leading companies the economy
Brokerage
Our trading room is one of the most dynamic in the Israeli market
Pluristem - initiating Coverage
Notwithstanding the impressive progress of the Company and its market positioning, the lack of approved treatments in the market and the numerous questions and concerns about the activity make pricing of Pluristem very difficult, similar to the other companies in the field. Accordingly, considering only the CLI indication, we have set a target price of $4.2 per share, with the recommendation of Buy.
